🇺🇸 FDA
Pipeline program

Hemlibra 150 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection, Hemlibra 150 mg/mL solution for injection, Hemlibra 150 mg/mL solution for injection, Hemlibra 150 mg/mL solution for injection

22-571/21U-0151

Approved small_molecule active

Quick answer

Hemlibra 150 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection, Hemlibra 150 mg/mL solution for injection, Hemlibra 150 mg/mL solution for injection, Hemlibra 150 mg/mL solution for injection for Congenital Haemophilia A is a Approved program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Disc Medicine
Indication
Congenital Haemophilia A
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials